Significant overexpression of urokinase‐type plasminogen activator in pancreatic adenocarcinoma using real‐time quantitative reverse transcription polymerase chain reaction

Background and Aims:  Overexpression of urokinase‐type plasminogen activator (uPA) has been shown to be strongly associated with an increased metastatic potential and poor prognosis in a variety of human malignancies. It was hypothesized that uPA would be overexpressed in highly metastatic pancreatic cancer. The aims of this study were to analyze uPA mRNA expression in pancreatic cancer and to correlate this to the expression of uPA protein and to the stage of the disease.

[1]  H. Kwaan.  The plasminogen-plasmin system in malignancy , 1992, Cancer and Metastasis Reviews.

[2]  M. Caputi,et al.  Urokinase‐mediated posttranscriptional regulation of urokinase‐receptor expression in non small cell lung carcinoma , 2003, International journal of cancer.

[3]  S. Dixon,et al.  Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase. , 2003, Experimental cell research.

[4]  I. Bartenjev,et al.  Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. , 2003, Oncology reports.

[5]  N. Brünner,et al.  Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue. , 2003, European journal of cancer.

[6]  E. Baker,et al.  The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. , 2003, European journal of cancer.

[7]  M. Ranson,et al.  Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2 , 2003, British Journal of Cancer.

[8]  H. Höfler,et al.  Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Czekay,et al.  Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins , 2003, The Journal of cell biology.

[10]  G. Rice,et al.  Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach , 2003, Proteomics.

[11]  K. Preissner,et al.  Binding of Urokinase Plasminogen Activator to gp130 via a Putative Urokinase-Binding Consensus Sequence , 2003, Biological chemistry.

[12]  J. Schneider,et al.  Accumulation of uPA – PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer , 2003, British Journal of Cancer.

[13]  Megumi Baba,et al.  Urokinase‐type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer , 2003, Cancer science.

[14]  I. Bièche,et al.  Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. , 2002, Anticancer research.

[15]  Helmut Burtscher,et al.  Identification of rat pancreatic carcinoma genes associated with lymphogenous metastasis. , 2002, Anticancer research.

[16]  M. Ranson,et al.  213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model , 2002, British Journal of Cancer.

[17]  S. Rosenberg.  New developments in the urokinase-type plasminogen activator system , 2001, Expert opinion on therapeutic targets.

[18]  T. Gress,et al.  TGF‐β–induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase‐2 and the urokinase plasminogen activator system , 2001, International journal of cancer.

[19]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[20]  R. Rasmussen.  Quantification on the LightCycler , 2001 .

[21]  S. Bustin.  Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. , 2000, Journal of molecular endocrinology.

[22]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[23]  Douglas B. Evans,et al.  Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA , 1999, Oncogene.

[24]  N. Lemoine,et al.  Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. , 1998, Cancer research.

[25]  T. Nakamura,et al.  Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. , 1998, The American journal of pathology.

[26]  D. Berger,et al.  Angiostatin generation by human pancreatic cancer. , 1998, The Journal of surgical research.

[27]  F. Real,et al.  The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro , 1998, Oncogene.

[28]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[29]  H. Friess,et al.  Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. , 1997, British Journal of Cancer.

[30]  V. Tkachuk,et al.  REGULATION AND ROLE OF UROKINASE PLASMINOGEN ACTIVATOR IN VASCULAR REMODELLING , 1996, Clinical and experimental pharmacology & physiology.

[31]  B. Nielsen,et al.  Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[32]  E. Hedley‐Whyte,et al.  Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.

[33]  H. Verspaget,et al.  Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. , 1995, European journal of cancer.

[34]  A. Nakao,et al.  Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. , 1993, The American journal of gastroenterology.

[35]  F. Jänicke,et al.  Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. , 1992, Biological chemistry Hoppe-Seyler.

[36]  R. Tsuchiya,et al.  UICC and Japanese stage classifications for carcinoma of the pancreas , 1991, International journal of pancreatology : official journal of the International Association of Pancreatology.